Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 13/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6011648 | 0.80 | SLC6A4 (0.42) | ADAM17SLC6A4MMP2MMP9MMP8 | |
| Hydrochloric Acid SCHEMBL6011657 | 0.79 | SLC6A4 (0.41) | KMT2AADAM17SLC6A4MMP2MMP9 | |
| SCHEMBL6011958 | 0.74 | ADAM17 (0.42) | ADAM17SLC6A4MMP9MMP8MMP13 | |
| SCHEMBL6011962 | 0.72 | HRH3 (0.51) | KMT2ALTA4HADAM17 | |
| SCHEMBL11459383 | 0.71 | LTA4H (0.52) | KMT2ALTA4HSLC6A4 | |
| SCHEMBL6011358 | 0.70 | GPR119 (0.43) | ADAM17MMP2MMP9MMP8MMP13 | |
| SCHEMBL7438835 | 0.70 | KMT2A (0.57) | KMT2ALTA4H | |
| SCHEMBL7439443 | 0.69 | LTA4H (0.56) | KMT2ALTA4H | |
| SCHEMBL7445314 | 0.69 | LTA4H (0.56) | KMT2ALTA4H | |
| SCHEMBL11458950 | 0.66 | LTA4H (0.50) | KMT2ALTA4HSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | CCR5, CCR2, CCR1 | KMT2A 4052/4885LTA4H 2628/4885ADAM17 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.